Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
Status:
Terminated
Trial end date:
2010-09-29
Target enrollment:
Participant gender:
Summary
This is an open label study of mepolizumab 750 mg intravenous in those subjects who
participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in
subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing
frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs
and symptoms of Hypereosinophilic Syndrome.